TY - JOUR AU - Nilsson, B. AU - Bumming, P. AU - Meis-Kindblom, J. M. AU - Oden, A. AU - Dortok, A. AU - Gustavsson, B. PY - 2005 DA - 2005// TI - Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden JO - Cancer VL - 103 UR - https://doi.org/10.1002/cncr.20862 DO - 10.1002/cncr.20862 ID - Nilsson2005 ER - TY - JOUR AU - Burkill, G. J. C. AU - Badran, M. AU - Al-Muderis, O. AU - Meirion-Thomas, J. AU - Judson, I. R. AU - Fisher, C. PY - 2003 DA - 2003// TI - Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread JO - Radiology VL - 226 UR - https://doi.org/10.1148/radiol.2262011880 DO - 10.1148/radiol.2262011880 ID - Burkill2003 ER - TY - JOUR AU - Corless, C. L. AU - Fletcher, J. A. AU - Heinrich, M. C. PY - 2004 DA - 2004// TI - Biology of gastrointestinal stromal tumors JO - J Clin Oncol Off J Am Soc Clin Oncol. VL - 22 UR - https://doi.org/10.1200/JCO.2004.05.140 DO - 10.1200/JCO.2004.05.140 ID - Corless2004 ER - TY - JOUR AU - Demetri, G. D. AU - Mehren, M. AU - Blanke, C. D. AU - Abbeele, A. D. AU - Eisenberg, B. AU - Roberts, P. J. PY - 2002 DA - 2002// TI - Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors JO - N Engl J Med VL - 347 UR - https://doi.org/10.1056/NEJMoa020461 DO - 10.1056/NEJMoa020461 ID - Demetri2002 ER - TY - JOUR AU - Oosterom, A. T. AU - Judson, I. AU - Verweij, J. AU - Stroobants, S. AU - Paola, E. D. AU - Dimitrijevic, S. PY - 2001 DA - 2001// TI - Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study JO - Lancet VL - 358 UR - https://doi.org/10.1016/S0140-6736(01)06535-7 DO - 10.1016/S0140-6736(01)06535-7 ID - Oosterom2001 ER - TY - JOUR AU - Dagher, R. AU - Cohen, M. AU - Williams, G. AU - Rothmann, M. AU - Gobburu, J. AU - Robbie, G. PY - 2002 DA - 2002// TI - Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors JO - Clin Cancer Res VL - 8 ID - Dagher2002 ER - TY - JOUR AU - Goodman, V. L. AU - Rock, E. P. AU - Dagher, R. AU - Ramchandani, R. P. AU - Abraham, S. AU - Gobburu, J. V. S. PY - 2007 DA - 2007// TI - Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma JO - Clin Cancer Res Off J Am Assoc Cancer Res. VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-2328 DO - 10.1158/1078-0432.CCR-06-2328 ID - Goodman2007 ER - TY - JOUR PY - 2013 DA - 2013// TI - FDA approves stivarga for GIST JO - Cancer Discov. VL - 3 UR - https://doi.org/10.1158/2159-8290.CD-NB2013-039 DO - 10.1158/2159-8290.CD-NB2013-039 ID - ref8 ER - TY - JOUR AU - Mehren, M. AU - Randall, R. L. AU - Benjamin, R. S. AU - Boles, S. AU - Bui, M. M. AU - Casper, E. S. PY - 2014 DA - 2014// TI - Gastrointestinal stromal tumors, version 2.2014 JO - J Natl Compr Cancer Netw JNCCN. VL - 12 UR - https://doi.org/10.6004/jnccn.2014.0080 DO - 10.6004/jnccn.2014.0080 ID - Mehren2014 ER - TY - JOUR AU - Corless, C. L. PY - 2005 DA - 2005// TI - PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.14.068 DO - 10.1200/JCO.2005.14.068 ID - Corless2005 ER - TY - JOUR AU - Hirota, S. AU - Isozaki, K. AU - Moriyama, Y. AU - Hashimoto, K. AU - Nishida, T. AU - Ishiguro, S. PY - 1998 DA - 1998// TI - Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors JO - Science VL - 279 UR - https://doi.org/10.1126/science.279.5350.577 DO - 10.1126/science.279.5350.577 ID - Hirota1998 ER - TY - JOUR AU - Heinrich, M. C. AU - Corless, C. L. AU - Blanke, C. D. AU - Demetri, G. D. AU - Joensuu, H. AU - Roberts, P. J. PY - 2006 DA - 2006// TI - Molecular correlates of imatinib resistance in gastrointestinal stromal tumors JO - J Clin Oncol Off J Am Soc Clin Oncol. VL - 24 UR - https://doi.org/10.1200/JCO.2006.06.2265 DO - 10.1200/JCO.2006.06.2265 ID - Heinrich2006 ER - TY - JOUR AU - Heinrich, M. C. AU - Maki, R. G. AU - Corless, C. L. AU - Antonescu, C. R. AU - Harlow, A. AU - Griffith, D. PY - 2008 DA - 2008// TI - Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.7461 DO - 10.1200/JCO.2007.15.7461 ID - Heinrich2008 ER - TY - STD TI - Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011. http://www.ncbi.nlm.nih.gov/pubmed/22089421. Accessed 18 Nov 2011. UR - http://www.ncbi.nlm.nih.gov/pubmed/22089421 ID - ref14 ER - TY - JOUR AU - Call, J. AU - Walentas, C. AU - Eickhoff, J. AU - Scherzer, N. PY - 2012 DA - 2012// TI - Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry JO - BMC Cancer. VL - 12 UR - https://doi.org/10.1186/1471-2407-12-90 DO - 10.1186/1471-2407-12-90 ID - Call2012 ER - TY - JOUR AU - Ng, E. H. AU - Pollock, R. E. AU - Munsell, M. F. AU - Atkinson, E. N. AU - Romsdahl, M. M. PY - 1992 DA - 1992// TI - Prognostic factors influencing survival in gastrointestinal leiomyosarcomas implications for surgical management and staging JO - Ann Surg VL - 215 UR - https://doi.org/10.1097/00000658-199201000-00010 DO - 10.1097/00000658-199201000-00010 ID - Ng1992 ER - TY - JOUR PY - 2010 DA - 2010// TI - Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients JO - J Clin Oncol. VL - 28 UR - https://doi.org/10.1200/JCO.2009.24.2099 DO - 10.1200/JCO.2009.24.2099 ID - ref17 ER - TY - JOUR AU - Graaf, W. T. A. AU - Tielen, R. AU - Bonenkamp, J. J. AU - Lemmens, V. AU - Verhoeven, R. H. A. AU - Wilt, J. H. W. PY - 2018 DA - 2018// TI - Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era JO - BJS VL - 105 UR - https://doi.org/10.1002/bjs.10809 DO - 10.1002/bjs.10809 ID - Graaf2018 ER - TY - JOUR AU - Joensuu, H. AU - Eriksson, M. AU - Sundby Hall, K. AU - Hartmann, J. T. AU - Pink, D. AU - Scuhtte, J. PY - 2012 DA - 2012// TI - One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor a randomized trial JO - JAMA VL - 307 UR - https://doi.org/10.1001/jama.2012.347 DO - 10.1001/jama.2012.347 ID - Joensuu2012 ER - TY - JOUR AU - Demetri, G. AU - Vanoosterom, A. AU - Garrett, C. AU - Blackstein, M. AU - Shah, M. AU - Verweij, J. PY - 2006 DA - 2006// TI - Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial JO - Lancet. VL - 368 UR - https://doi.org/10.1016/S0140-6736(06)69446-4 DO - 10.1016/S0140-6736(06)69446-4 ID - Demetri2006 ER - TY - STD TI - Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61857-1/abstract. Accessed 26 Nov 2012. UR - http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61857-1/abstract ID - ref21 ER - TY - JOUR AU - Demetri, G. D. AU - Reichardt, P. AU - Kang, Y. -. K. AU - Blay, J. -. Y. AU - Joensuu, H. AU - Schaefer, K. PY - 2016 DA - 2016// TI - Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST) JO - J Clin Oncol. VL - 34 UR - https://doi.org/10.1200/jco.2016.34.4_suppl.156 DO - 10.1200/jco.2016.34.4_suppl.156 ID - Demetri2016 ER - TY - JOUR AU - George, S. AU - Wang, Q. AU - Heinrich, M. C. AU - Corless, C. L. AU - Zhu, M. AU - Butrynski, J. E. PY - 2012 DA - 2012// TI - Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.9394 DO - 10.1200/JCO.2011.39.9394 ID - George2012 ER - TY - JOUR AU - Ben-Ami, E. AU - Barysauskas, C. M. AU - Mehren, M. AU - Heinrich, M. C. AU - Corless, C. L. AU - Butrynski, J. E. PY - 2016 DA - 2016// TI - Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw228 DO - 10.1093/annonc/mdw228 ID - Ben-Ami2016 ER - TY - JOUR AU - Dewaele, B. AU - Wasag, B. AU - Cools, J. AU - Sciot, R. AU - Prenen, H. AU - Vandenberghe, P. PY - 2008 DA - 2008// TI - Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a Heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-08-0533 DO - 10.1158/1078-0432.CCR-08-0533 ID - Dewaele2008 ER - TY - STD TI - Heinrich MC, Griffith DJ, McKinley A, Patterson J, Presnell A, Ramachandran A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2012. http://clincancerres.aacrjournals.org/content/early/2012/06/27/1078-0432.CCR-12-0625. Accessed 28 June 2012. UR - http://clincancerres.aacrjournals.org/content/early/2012/06/27/1078-0432.CCR-12-0625 ID - ref26 ER - TY - JOUR AU - Evans, E. K. AU - Gardino, A. K. AU - Kim, J. L. AU - Hodous, B. L. AU - Shutes, A. AU - Davis, A. PY - 2017 DA - 2017// TI - A precision therapy against cancers driven by KIT/PDGFRA mutations JO - Sci Transl Med. VL - 9 UR - https://doi.org/10.1126/scitranslmed.aao1690 DO - 10.1126/scitranslmed.aao1690 ID - Evans2017 ER - TY - JOUR AU - Pender, A. AU - Jones, R. L. PY - 2017 DA - 2017// TI - Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma JO - Clin Pharmacol Adv Appl. VL - 4 ID - Pender2017 ER - TY - JOUR AU - Weldon, C. B. AU - Madenci, A. L. AU - Boikos, S. A. AU - Janeway, K. A. AU - George, S. AU - Mehren, M. PY - 2017 DA - 2017// TI - Surgical management of wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Pediatric and Wildtype GIST Clinic JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.68.6733 DO - 10.1200/JCO.2016.68.6733 ID - Weldon2017 ER - TY - STD TI - Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, et al. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol. 2011. http://www.ncbi.nlm.nih.gov/pubmed/22119758. Accessed 29 Nov 2011. UR - http://www.ncbi.nlm.nih.gov/pubmed/22119758 ID - ref30 ER - TY - JOUR AU - Montemurro, M. AU - Gelderblom, H. AU - Bitz, U. AU - Schütte, J. AU - Blay, J. Y. AU - Joensuu, H. PY - 2013 DA - 2013// TI - Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: a retrospective analysis JO - Eur J Cancer Oxf Engl. VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.10.009 DO - 10.1016/j.ejca.2012.10.009 ID - Montemurro2013 ER - TY - JOUR AU - Park, S. H. AU - Ryu, M. H. AU - Ryoo, B. Y. AU - Im, S. A. AU - Kwon, H. C. AU - Lee, S. S. PY - 2012 DA - 2012// TI - Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group JO - Invest New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-012-9795-9 DO - 10.1007/s10637-012-9795-9 ID - Park2012 ER - TY - JOUR AU - Sawaki, A. AU - Nishida, T. AU - Doi, T. AU - Yamada, Y. AU - Komatsu, Y. AU - Kanda, T. PY - 2011 DA - 2011// TI - Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor JO - Cancer. VL - 117 UR - https://doi.org/10.1002/cncr.26120 DO - 10.1002/cncr.26120 ID - Sawaki2011 ER - TY - JOUR AU - Raut, C. P. AU - Posner, M. AU - Desai, J. AU - Morgan, J. A. AU - George, S. AU - Zahrieh, D. PY - 2006 DA - 2006// TI - Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.05.3439 DO - 10.1200/JCO.2005.05.3439 ID - Raut2006 ER - TY - JOUR AU - DeMatteo, R. P. AU - Maki, R. G. AU - Singer, S. AU - Gonen, M. AU - Brennan, M. F. AU - Antonescu, C. R. PY - 2007 DA - 2007// TI - Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor JO - Ann Surg VL - 245 UR - https://doi.org/10.1097/01.sla.0000236630.93587.59 DO - 10.1097/01.sla.0000236630.93587.59 ID - DeMatteo2007 ER - TY - JOUR AU - Yeh, C. -. N. AU - Wang, S. -. Y. AU - Tsai, C. -. Y. AU - Chen, Y. -. Y. AU - Liu, C. -. T. AU - Chiang, K. -. C. PY - 2017 DA - 2017// TI - Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: a prospective cohort study JO - Int J Surg Lond Engl. VL - 39 UR - https://doi.org/10.1016/j.ijsu.2017.01.045 DO - 10.1016/j.ijsu.2017.01.045 ID - Yeh2017 ER - TY - JOUR AU - Kang, Y. -. K. AU - Ryu, M. -. H. AU - Yoo, C. AU - Ryoo, B. -. Y. AU - Kim, H. J. AU - Lee, J. J. PY - 2013 DA - 2013// TI - Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial JO - Lancet Oncol. VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70453-4 DO - 10.1016/S1470-2045(13)70453-4 ID - Kang2013 ER - TY - JOUR AU - Demetri, G. D. AU - Garrett, C. R. AU - Schöffski, P. AU - Shah, M. H. AU - Verweij, J. AU - Leyvraz, S. PY - 2012 DA - 2012// TI - Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure JO - Clin Cancer Res Off J Am Assoc Cancer Res. VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-3005 DO - 10.1158/1078-0432.CCR-11-3005 ID - Demetri2012 ER - TY - JOUR AU - Reichardt, P. AU - Kang, Y. -. K. AU - Rutkowski, P. AU - Schuette, J. AU - Rosen, L. S. AU - Seddon, B. PY - 2015 DA - 2015// TI - Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib JO - Cancer VL - 121 UR - https://doi.org/10.1002/cncr.29220 DO - 10.1002/cncr.29220 ID - Reichardt2015 ER - TY - JOUR AU - Cassier, P. A. AU - Ducimetiere, F. AU - Lurkin, A. AU - Ranchere-Vince, D. AU - Scoazec, J. -. Y. AU - Bringuier, P. -. P. PY - 2010 DA - 2010// TI - A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region JO - Br J Cancer VL - 103 UR - https://doi.org/10.1038/sj.bjc.6605743 DO - 10.1038/sj.bjc.6605743 ID - Cassier2010 ER -